Salute e Benessere

SmartCella strengthens team by recruiting Dr. Nina Bauer as Chief Business…

Niklas Prager, CEO of SmartCella, comments: "We are thrilled to welcome Nina to the SmartCella group, she possesses a versatile and unique mix of competencies across the fields of novel modality and biotherapeutics as well as manufacturing technologies and process improvements to enable global therapy access. She is equally familiar with managing strategic discussions on a board or leadership level as with working hands-on in prototyping labs or GMP facilities. As we are now taking the next…
PR Newswire
03/01/2024

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study…

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody - drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024. /2 study of its novel antibody - drug conjugate (ADC) cancer therapy targeting TROP2. OBI plans to enroll patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and gastric cancer (GC), although several other cancers are also...
Nasdaq GlobeNewswire
03/01/2024

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical…

Miquel Vila-Perelló, Ph.D., Chief Executive Officer, and co-founder of SpliceBio, said: "Dr Girach joins SpliceBio at an important time of growth as we accelerate our lead program targeting Stargardt disease into clinical development. Dr Girach's unrivalled experience in the field of ophthalmology and genetic medicines will be instrumental as we further strengthen our leadership team and maximize the potential of our proprietary Protein Splicing platform." Miquel Vila-Perelló, Ph.D…
PR Newswire
03/01/2024

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between…

The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular Degeneration (AMD)Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept)...
Nasdaq GlobeNewswire
03/01/2024

Velocity expands to 17 sites in Europe

Velocity becomes one of largest site organisations in Europe in addition to being the largest in the U.S.Adds Oncology to therapeutic capabilityLONDON, Jan.03, 2024(GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute...
Nasdaq GlobeNewswire
03/01/2024

Sanner Group strengthens medical device design and development capabilities with…

Sanner Group strengthens medical device design and development capabilities with the acquisition of Springboard Pro 3 January 2024 - Sanner Group, a leading global healthcare packaging manufacturer and medical device Contract Development and Manufacturing Organisation (CDMO) has acquired Springboard, a specialist in the design and development of medical devices for regulated markets.The acquisition of Springboard is in line with Sanner Group's goal to build a suite of world leading...
Nasdaq GlobeNewswire
03/01/2024

Nicox : Termination of the liquidity contract with Kepler Cheuvreux

Press ReleaseNicox : Termination of the liquidity contract with Kepler Cheuvreux January 3, 2024 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the termination of the liquidity contract dated August 3 rd, 2020 entered into with Kepler Cheuvreux (the “Contract”). Such termination is effective as of January 1 st, 2024. When the Contract was implemented, the...
Nasdaq GlobeNewswire
03/01/2024

Sequana Medical granted US CPT® III reimbursement codes for alfapump® system

PRESS RELEASEStrengthens US reimbursement positionBuilds upon PMA application submitted to the US FDA on 27 December 2023Ghent, Belgium – 03 January 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the American Medical Association (AMA) has issued six new Category III Current Procedural Terminology (CPT III) codes for...
Nasdaq GlobeNewswire
03/01/2024

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial…

Company Announcement COPENHAGEN, Denmark; January 3, 2024 –Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...
Nasdaq GlobeNewswire
03/01/2024

LG STYLER INTRODUCES NEW ERA IN CLOTHING CARE MANAGEMENT AT CES 2024

A first for the LG Styler lineup, the new model features a handheld, high-pressure steamer that makes it easier to remove wrinkles from shirts and other garments, and saves the hassle of having to use a separate iron. Users can simply hang their wrinkled clothes inside the door, take out the steamer attached to the bottom of the Styler, and initiate the steam process with the press of a button. The steamer employs powerful, high-pressure steam to penetrate garments, leaving them smooth and soft…
PR Newswire
03/01/2024

The Body Shop becomes the first global beauty brand with 100% vegan product…

The Body Shop was also the first beauty retailer to campaign against animal testing in cosmetics in 1989, with a fundamental belief that animals should not be harmed in the pursuit of beauty. While the fight continues for a worldwide ban on animal testing in cosmetics, for The Body Shop, a fully vegan product range is the next milestone in cruelty-free beauty. The Body Shop was also the first beauty retailer to campaign against animal testing in cosmetics in 1989, with a fundamental belief…
PR Newswire
03/01/2024

Ultimovacs ASA: Mandatory notification of trade by primary insider

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachments 20240102 - Ultimovacs Notification of trade - CDS1 - KRT 150020240102 - Ultimovacs Notification of trade - CDS2 - KRT 1500
Nasdaq GlobeNewswire
02/01/2024

Number of voting rights as of December 31, 2023

Nicox SA Société anonyme with a registered capital of € 50,170,498 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On January 2nd, 2024, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l'AMF) As of December 31, 2023 Total number of shares...
Nasdaq GlobeNewswire
02/01/2024

Cosmetic Implants Market to Grow at a Robust CAGR of 9.67%, Accruing Valuation…

Request Sample PDF of the Report:https://www.kingsresearch.com/request-sample/cosmetic-implants-market-283 Request Sample PDF of the Report:https://www.kingsresearch.com/request-sample/cosmetic-implants-market-283 Trending Now: Sientra® Takes Center Stage with High-Strength Cohesive Silicone Gel Breast Implants Launch inCanada InJuly 2023, Canadian plastic surgeons gained access to the latest generation of breast implants with the approval of Sientra, the first manufacturer...
PR Newswire
02/01/2024

Blood Transfusion Diagnostics Market Size to Reach USD 6.6 billion, at a 5.0%…

Focus on donor health tracking and screening methodologies improves blood quality. Continuous monitoring and assessment of donor health indicators enhance the safety and reliability of donated blood, influencing diagnostics' demand. Ongoing research into novel biomarkers for blood typing and compatibility assessments drives innovation. Identifying specific markers for quicker, more accurate diagnostics enhances transfusion safety and efficiency. Focus on donor health tracking and screening...
PR Newswire
02/01/2024

Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Media Release COPENHAGEN, Denmark; January 2, 2024Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 42 ndAnnual J.P. Morgan Healthcare Conference in San Francisco at 11:15 AM PST / 2:15 PM EST / 8:15 PM CET on January 10, 2024. The live and archived webcast of the presentation will be available on Genmab's website at https://ir.genmab.com/events-and-presentations#content . About Genmab Genmab is an...
Nasdaq GlobeNewswire
02/01/2024

BBS-Bioactive Bone Substitutes Plc: Kimmo Tyni appointed as Product Director of…

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 2 January 2024 at 04.30 PM (EET) Kimmo Tyni appointed as Product Director of BBS-Bioactive Bone Substitutes PlcBBS-Bioactive Bone Substitutes Plc has appointed Kimmo Tyni (B. Sc. Tech.) as Product Director as of 15.1.2024. The current Product Director Jussi Jukka will transfer from company's service, to outside of BBS. Tyni will work as a member of the management team of BBS and report to the CEO. Tyni has previous experience in...
Nasdaq GlobeNewswire
02/01/2024

Allorion Therapeutics Announces Exclusive Option and Global License Agreement…

Fang Li, PhD., Cofounder and Chief Scientific Officer of Allorion remarked, "Allorion's EGFR L858R allosteric inhibitor is designed to address mechanisms of resistance to current EGFR inhibitors and has the potential to enhance their activity, when used in combination. We are excited to enter into this agreement with AstraZeneca, a global leader in this field, to advance our EGFR inhibitor into the clinic and explore potential combinations with other EGFR targeting molecules such as…
PR Newswire
02/01/2024

Novel Device Facilitates Successful No-Shave FUE Transplants for Long Hair with…

The device's versatility was further demonstrated in the study by its success in performing no-shave long hair FUE in black patients of African descent, who are typically deemed challenging in even shaved head FUE procedures. The device's versatility was further demonstrated in the study by its success in performing no-shave long hair FUE in black patients of African descent, who are typically deemed challenging in even shaved head FUE procedures. Featuring a proprietaryintuitive punch...
PR Newswire
02/01/2024

Junshi Biosciences Announces Approval of the Supplemental New Drug Application…

®, product code: JS001) in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (“NSCLC”) has been approved by the National Medical Products Administration. This is the first approved perioperative therapy for lung cancer in China and the second worldwide. Lung cancer is currently the world's second most prevalent malignant tumor, with the...
Nasdaq GlobeNewswire
02/01/2024

Medical Aesthetic Devices Market to Attain a Valuation of USD 25.1 billion by…

The pervasive impact of social media platforms shapes beauty ideals, prompting a surge in aesthetic treatments. Increased exposure to curated images and influencer endorsements drives consumer interest in procedures, influencing market growth. The evolving societal norms regarding male grooming and appearance lead to an upsurge in demand for aesthetic treatments among men. The growing acceptance of cosmetic procedures among male demographics becomes a pivotal driver fueling market expansion. ...
PR Newswire
02/01/2024

IMC Announces the Conclusion of the Planning and Construction Legal Proceedings

About IM Cannabis Corp. About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients inIsraelandGermany, two of the largest medical cannabis markets. The Company has recently exited operations inCanadato pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets,IsraelandGermany. The Company leverages a transnational ecosystem powered by...
PR Newswire
02/01/2024

EndoQuest™ Robotics Accepted for Inclusion in FDA's Safer Technologies Program…

The FDA's Safer Technologies Program is designed for devices expected to substantially enhance the safety of existing treatment options. Being part of this program means our product will benefit from a streamlined development and review process, ensuring expedited access for patients without compromising the rigorous safety and efficacy standards for FDA approval. The FDA's Safer Technologies Program is designed for devices expected to substantially enhance the safety of existing treatment…
PR Newswire
02/01/2024

Insider Information, profit warning: Nexstim Oyj specifies its guidance for 2023

Company Announcement, Helsinki, 2 January 2024 at 9 AM (EET) Insider Information, profit warning: Nexstim Oyj specifies its guidance for 2023 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces based on its updated business forecast, that the Company expects that its comparable net sales will grow in 2023 and its EBITDA (operating result before depreciations) for the financial year will be negative. The net sales and the comparable net sales for the full year of 2023…
Nasdaq GlobeNewswire
02/01/2024
Altri  Comunicati